title: Safety profile of extended-release niacin in the AIM-HIGH trial.
authors.affiliation: Libin Cardiovascular Institute, Calgary, AB, Canada.
authors.forename: Todd J
authors.initials: TJ
authors.lastname: Anderson
authors.forename: William E
authors.initials: WE
authors.lastname: Boden
authors.forename: Patrice
authors.initials: P
authors.lastname: Desvigne-Nickens
authors.forename: Jerome L
authors.initials: JL
authors.lastname: Fleg
authors.forename: Moti L
authors.initials: ML
authors.lastname: Kashyap
authors.forename: Ruth
authors.initials: R
authors.lastname: McBride
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Probstfield
mesh_terms: D050197:Atherosclerosis / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D009525:Niacin / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D003692:Delayed-Action Preparations; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009525:Niacin